Predictors of Response to Targeted Therapy in Renal Cell Carcinoma

Eisengart, Laurie J.; MacVicar, Gary R.; Yang, Ximing J.
May 2012
Archives of Pathology & Laboratory Medicine;May2012, Vol. 136 Issue 5, p490
Academic Journal
Context.-The prognosis for patients with metastatic renal cell carcinoma is poor, with an average 5-year survival of approximately 10%. Use of traditional cytokine therapy, specifically high-dose interleukin 2, is limited by significant toxicity. Better understanding of the molecular pathogenesis of renal cell carcinoma has led to the development of targeted therapies to inhibit specific cellular pathways leading to tumorigenesis. These drugs provide improved survival with a more favorable toxicity profile. There is ongoing investigation of markers that predict response of an individual patient to different targeted therapies. Objective.-To explain the molecular basis for vascular endothelial growth factor inhibitor (antiangiogenic) and mammalian target of rapamycin inhibitor therapies for renal cell carcinoma, summarize the clinical trials demonstrating the effectiveness of these drugs, and describe the biomarkers shown to correlate with outcome in patients treated with targeted therapy. Data Sources.-All included sources are from peer-reviewed journals in PubMed (US National Library of Medicine). Conclusion.-Emerging evidence shows promise that biomarkers will be useful for predicting an individual patient's response to targeted therapy, leading to a more personalized approach to treating renal cell carcinoma.


Related Articles

  • Targeted Therapies and Predictive Markers in Epithelial Malignancies of the Gastrointestinal Tract. McIntire, Maria; Redston, Mark // Archives of Pathology & Laboratory Medicine;May2012, Vol. 136 Issue 5, p496 

    Context.-In recent years, there has been a tremendous amount of interest in the development of targeted therapies for the treatment of human cancers. Increased understanding of the specific molecular pathways and driver mutations critical to cancer cell growth have allowed the development of...

  • Exploring anti-VEGF therapy for orbital vascular lesions. Guttman Krader, Cheryl // Ophthalmology Times;10/15/2016, Vol. 41 Issue 17, p18 

    The article presents a discussion about using anti-vascular endothelial growth factor (VEGF) treatment for orbital vascular lesions, adapted from the presentation delivered by Mayo Clinic ophthalmology resident Elizabeth A. Atchison at the 2015 annual meeting of the American Academy of...

  • Remission of Psoriasis and Psoriatic Arthritis During Bevacizumab Therapy for Renal Cell Cancer. Datta-Mitra, Ananaya; Riar, Navdeep K.; Raychaudhuri, Siba P. // Indian Journal of Dermatology;Nov/Dec2014, Vol. 59 Issue 6, p1 

    Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still...

  • Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy. Cohen, Alexander C.; Roane, Brandon M.; Leath III, Charles A. // Drugs;Feb2020, Vol. 80 Issue 3, p217 

    While screening programs and HPV vaccination have decreased the incidence of cervical cancer, still over 13,000 cases occur in the USA annually. Early-stage cervical cancer has an excellent long-term prognosis, with 5-year survival for localized disease being > 90%. Survival decreases markedly...

  • Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Edrei, Y; Gross, E; Corchia, N; Abramovitch, R // British Journal of Cancer;8/7/2012, Vol. 107 Issue 4, p658 

    Background:The poor prognosis of patients with colorectal-cancer liver metastases (CRLM) and the insufficiency of available treatments have raised the need for alternative curative strategies. We aimed to assess the therapeutic potential of TL-118, a new anti-angiogenic drug combination, for...

  • Titration of RCC Tx may be needed for optimum efficacy. Kuznar, Wayne // Urology Times;May2012, Vol. 40 Issue 6, p30 

    The article focuses on the secondary analysis of a large international and randomized trial which indicate the necessity of dose titration of the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) for patients with renal cell carcinoma (RCC). The study reveals that axitinib...

  • Molecular Therapy Beyond Sorafenib in HCC: New Pathways, Targets Being Explored. Kuznar, Wayne // Oncology Pharmacist;May2014, Vol. 7 Issue 2, p15 

    No abstract available.

  • Novel VEGF inhibitor may play role in advanced RCC. Kuznar, Wayne // Urology Times;Apr2013, Vol. 41 Issue 5, p14 

    The article presents the study of Robert J. Motzer that investigates the role of novel vascular endothelial growth factor (VEGF) in the survival rates of patients with advanced renal cell carcinoma (RCC) in Orlando, Florida. He did a research on 257 patients who received sorafenib and where 70%...

  • Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. Escudier, Bernard; Albiges, Laurence; Sonpavde, Guru // Drugs;2013, Vol. 73 Issue 5, p427 

    The armamentarium for the systemic therapy of advanced renal cell carcinoma (RCC) has undergone dramatic changes over the past 6 years. While high-dose interleukin (IL)-2 remains an option for highly selected good and intermediate risk patients with clear-cell histology because of durable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics